Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 10/20 | 0.62 |
| ▸ | PPARA | Q07869 | 10/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563293 | 0.92 | KDR (0.60) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL6955816 | 0.89 | FFAR1 (0.61) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4034465 | 0.88 | RAB9A (0.53) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4746469 | 0.88 | PPARG (0.73) | PPARGPPARA | |
| SCHEMBL6157414 | 0.87 | KDR (0.67) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL6970285 | 0.87 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL4745022 | 0.86 | FFAR1 (0.70) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4852533 | 0.86 | FFAR1 (0.60) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL19392906 | 0.85 | FFAR1 (0.68) | FFAR1PPARGPPARAKDRMAPT | |
| SCHEMBL4035264 | 0.85 | FFAR1 (0.51) | FFAR1PPARGPPARAKDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008006044-A2 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20050239854-A1 | Body weight gain inhibitors | SUGIYAMA YASUO | 2005-10-27 | — | — | US | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-6777435-B1 | RETINOID-RELATED RECEPTOR FUNCTION REGULATING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1224178-B1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-25 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| US-5972970-A | COMPOUNDS SUCH AS 5-(3-(2-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL) ETHOXYL-5-PYRIDYL)PROPYL)-2,4-OXAZOLIDINEDIONE; ADMINISTERING TO TREAT A MAMMAL SUFFERING FROM DIABETES OR HYPERLIPIDEMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0612743-B1 | Oxazolidinedione derivatives, their production and use in lowering blood sugar and lipid levels | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-10 | — | — | EP | disclosed |
| US-5665748-A | ANTIDIABETIC, HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-09 | — | — | US | disclosed |
| US-5504097-A | TREATING ATHEROSCLEROSIS BY ADMINISTERING AN ANTILIPEMIC OR ANTICHOLESTEROL AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-02 | — | — | US | disclosed |
| US-5459154-A | Enzyme inhibitors as antiinflammatory agents and treatment of atherosclerosis | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0612743-A1 | Oxazolidinedione derivatives, their production and use in lowering blood sugar and lipid levels | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | FFAR1 53/4885PPARG 401/4885PPARA 152/4885 |
| US-20050239854-A1 | Body weight gain inhibitors | PPARG, GPR119, PPARA | FFAR1 43/4885PPARG 1/4885PPARA 3/4885 |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | GPR119, LIPC, CEL | FFAR1 14/4885PPARG 205/4885PPARA 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.